导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.54% | 1383/4773 |
| 近一周 | -1.15% | 1737/5465 |
| 近一月 | -2.17% | 1505/5421 |
| 近一季 | -7.47% | 2832/5231 |
| 近半年 | -2.72% | 2250/4920 |
| 近一年 | 7.70% | 1435/4394 |
| 近两年 | 65.56% | 1091/2954 |
| 近三年 | 37.44% | 829/2253 |
| 成立以来 | 261.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.46% 1267/4961 |
15.73% 1638/5312 |
- - |
- - |
| 2025 | 29.67% 1385/4813 |
2.30% 1410/3635 |
3.23% 1092/4076 |
22.16% 1677/4524 |
0.51% 1964/4813 |
| 2024 | 6.18% 1783/3463 |
-1.00% 1164/2808 |
-1.44% 1066/3014 |
9.13% 2713/3129 |
-0.28% 1367/3463 |
| 2023 | -8.98% 1080/2656 |
5.72% 758/2280 |
-4.35% 1146/2385 |
-5.70% 1362/2515 |
-4.54% 1087/2655 |
| 2022 | -16.46% 482/2207 |
-11.36% 501/1919 |
3.85% 1082/2016 |
-10.60% 430/2113 |
1.51% 1243/2208 |
| 2021 | 21.79% 157/1822 |
-0.05% 326/1255 |
11.19% 387/1330 |
7.31% 191/1466 |
2.12% 697/1822 |
| 2020 | 27.23% 588/1250 |
-6.06% 452/1028 |
21.13% 246/1067 |
10.20% 574/1164 |
1.46% 1029/1184 |
| 2019 | 27.63% 538/1092 |
31.08% 214/754 |
-8.14% 579/804 |
0.01% 569/850 |
5.98% 662/918 |
| 2018 | -31.39% 495/834 |
- - |
- - |
- - |
-12.35% 438/691 |
| 2017 | 3.21% 428/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.16% 95/605 |
- - |
- - |
- - |
- - |
| 2015 | 64.41% 6/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信中证500指数增强A VS. 长安沪深300非周期A(740101) |